Guizhou Cancer Hospital

Effects of self-acupressure on the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a phase III randomised controlled trial

PURPOSE: To explore the effectiveness and safety of self-acupressure intervention on the fatigue-sleep disturbance-depression symptom cluster (FSDSC) among breast cancer (BC) survivors and to explore within-trial costs associated with the intervention. METHODS: Eligible participa...

Comparing the efficacy of bronchial artery chemoembolization combined with anlotinib versus anlotinib alone in the treatment of advanced non-small cell lung cancer

To compare the clinical effectiveness and safety of addition of anlotinib to bronchial artery chemoembolization (BACE) compared to anlotinib alone in the treatment of stage IIIA-IIIB non-small cell lung cancer (NSCLC) with no mutated driver genes. The clinical data of patients wi...

Neoadjuvant Anbenitamab and HB1801 in ERBB2 -Positive Breast Cancer

IMPORTANCE The combination of neoadjuvant taxanes with trastuzumab and pertuzumab remains the cornerstone treatment strategy in ERBB2 -positive breast cancer. Anbenitamab (a ERBB2 -biparatopic antibody that induces profound receptor clustering) and HB1801 (a solvent-free albumin-...

Exploring the treatment of liver cancer with Gehua Hugan Gao based on bioinformatics, network pharmacology, and molecular docking

Gehua Hugan Gao (GHHGG) is a traditional Chinese medicine paste that is chiefly used to treat liver cancer. However, the potential impact of GHHGG on liver cancer remains unclear. We explored how GHHGG treats liver cancer using bioinformatics, network pharmacology, and molecular...

Clinical phenotype, family segregation, and follow-up of pediatric distal renal tubular acidosis associated with a homozygous SLC4A1 p.G701D variant

<title>Abstract</title> <bold>Background</bold> We report a case of SLC4A1-related distal renal tubular acidosis (dRTA) in a child with marked skeletal deformities, confirmed by family segregation analysis, and describe the clinical features, genetic findings, and follow-up chang...

Anlotinib combined with almonertinib reverses almonertinib resistance in lung adenocarcinoma by inhibiting the c-MET/PI3K/AKT pathway

Almonertinib resistance poses a major challenge in treating lung adenocarcinoma (LUAD) with epidermal growth factor receptor (EGFR) mutations. Research indicates that the c-MET/PI3K/AKT signaling pathway and epithelial-mesenchymal transition (EMT) are closely associated with resi...